Raymond James initiates Alumis stock coverage citing psoriasis drug potential

Alumis raised approximately $345.1M in an upsized public offering via sale of over 20M shares at $17 each (including full exercise of the underwriters' option). Multiple firms initiated/updated coverage: Raymond James Strong Buy PT $46, Stifel Buy PT $44, Chardan Buy PT $37, and Guggenheim raised its PT to $32 from $18, citing positive Phase III results for envudeucitinib (a next‑generation TYK2 inhibitor). The company plans to file an NDA in H2 2026 and will present full data at the AAD conference (Mar 27–31); Raymond James expects a launch that could exceed investor expectations.

Analysis

The market is treating the story as a clinical differentiation narrative rather than a simple pipeline bet; that makes payer and formulary mechanics the real arbiter of eventual revenue. If the molecule’s profile meaningfully lowers administration burden or total cost-of-care vs injectables, expect rapid contracting conversations with specialty pharmacy benefit managers that can flip share within 6–18 months of launch.

The enlarged cash buffer materially de-risks near-term dilution and gives the company optionality to fund a focused commercial rollout or buy targeted real-world evidence packages — both high ROI uses before peak sales are proven. Operationally, a small-molecule oral eliminates cold-chain logistics and high-cost biologics manufacturing scale, meaning per-patient COGS can be structurally lower; that improves margin leverage but shifts the battle to marketing, formulary access, and head-to-head perception.

Principal tail risks: (1) class safety/regulatory headlines that trigger broad payer caution and prescribing inertia, (2) large-cap competitors using bundled contracting to defend formulary position, and (3) a softer-than-expected real-world differentiation vs established TYK2/biologic therapies. Time-horizons are staggered: near-term readouts move price on sentiment (days–weeks); regulatory and payer outcomes drive valuation over 12–36 months. The asymmetric payoff favors option-enabled exposure sized to survive binary outcomes while capturing upside from successful market penetration.

Key Decisions for Investors

• Trade 1 — Long-call-spread (directional, limited loss): Buy a 9–12 month ALMS call 20–35% OTM and sell a higher strike 60–80% OTM to fund ~60–70% of premium. Size 0.5–1.0% NAV. Rationale: captures upside from positive clinical/regulatory sequencing while capping premium lost to theta; expected payoff 3x–6x on approval + good launch; loss limited to premium (~100%).
• Trade 2 — Pair trade (relative value; hedge of commercial execution): Go long ALMS equity = 1% NAV and short JNJ = 0.25% NAV as a partial hedge to sector/payer moves for 6–12 months. Rationale: isolates molecule-specific upside while limiting portfolio beta; risk: JNJ downside could outsize if market-wide selloff occurs, reward: asymmetric if ALMS demonstrates clear clinical/payer wins.
• Trade 3 — Volatility capture (post-catalyst): Plan to sell ALMS 2–6 week call spreads only after a positive headline-driven pop to capture IV crush; target 30–40% of realized pop in premium collected. Size small (0.25–0.5% NAV). Rationale: most binary biotech events lead to large IV decay — selling premium after the event is favorable; risk is sustained trend continuation requiring quick stop at 20–30% adverse move.
• Trade 4 — Event hedge (downside protection): If holding meaningful ALMS exposure into regulatory/payer milestones, buy a cheap long-dated put (1-year) or collar to limit downside to ~30–40% while allowing upside participation. Size depending on conviction; preserves upside optionality while capping tail losses from safety/regulatory shocks.